Current possibilities of pharmacological correction of neuroimmune joint damage in patients with knee osteoarthritis in long COVID conditions
Objective: to evaluate the efficacy and safety of the parenteral form of pharmaceutical chondroitin sulfate (CS) in neuroimmune joint damage in patients with early knee osteoarthritis (OA) in long COVID.Patients and methods. An open prospective controlled randomized study was conducted, its duration...
Saved in:
Main Authors: | I. V. Sarvilina, I. S. Dydykina, A. M. Lila |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2022-06-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/1299 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis
by: E. P. Sharapova, et al.
Published: (2021-08-01) -
Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard
by: I. Yu. Torshin, et al.
Published: (2021-02-01) -
Prospects for the use of chondroitin sulfate and glucosamine sulfate with osteoarthritis associated with pathology of the kidneys and urinary system
by: I. Yu. Torshin, et al.
Published: (2020-04-01) -
Acute issues in the pharmacotherapy of hand osteoarthritis
by: O. A. Gromova, et al.
Published: (2021-02-01) -
Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis
by: I. V. Sarvilina, et al.
Published: (2020-02-01)